On July 23, Thermo Fisher Scientific rose 3.71% in pre-market trading, trading at $533.96/share, with turnover of $2.6074 million. The rebound comes as the company released its second-quarter earnings report before market open, with market consensus expecting year-over-year revenue growth of approximately 9.55% and adjusted earnings per share of $5.71.
The pre-market gain follows a sharp sector-wide selloff on July 21, when industry leader Danaher plunged 13.15%, dragging life sciences tools stocks lower collectively. Thermo Fisher Scientific fell nearly 5% that day amid broad-based risk aversion, compounded by the approaching earnings window that amplified investor caution. The current rebound signals that the actual earnings release has alleviated panic sentiment triggered by the peer-driven decline.
For context, in Q1 the company reported adjusted EPS of $5.44, beating the $5.24 consensus by 3.82%, on revenue of $11.005 billion versus expectations of $10.853 billion. Management previously raised full-year revenue guidance to $47.3-$48.1 billion and set long-term targets of 7% organic revenue CAGR with low-double-digit adjusted EPS growth.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments